‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Dracey Poore, Director Of Biosimilars, Discusses Recent And Future Market Developments
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
